ImmuPharma (LON:IMM) Stock Price Up 25.3% - Here's What Happened

Key Points

• ImmuPharma plc shares surged by 25.3% on Monday, reaching a high of GBX 19.35 ($0.26) amid increased trading volume.
• The company reported a net margin of 3,519.56% but has a negative return on equity of 131.41% and is forecasted to post a loss of over £339 per share for the current year.
• ImmuPharma is a specialty biopharmaceutical company known for developing peptide-based therapeutics, including Lupuzor™, which targets autoimmune diseases.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) rose 25.3% on Monday . The company traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.51 ($0.24). Approximately 58,099,867 shares traded hands during mid-day trading, an increase of 591% from the average daily volume of 8,404,609 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Price Performance

The business has a fifty day moving average price of GBX 3.12 and a two-hundred day moving average price of GBX 2.91. The firm has a market capitalization of £87.51 million, a price-to-earnings ratio of -1,967.53 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, research analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.